EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 3.0

Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis

Aaron B Holley, Christopher S King, Jeffrey L Jackson, Lisa K Moores

Thrombosis · 2010

DOI: 10.1155/2010/540386 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Thrombosis, 2010. Verfasst von Aaron B Holley und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary/Critical Care/Sleep Medicine, Walter Reed Army Medical Center, Pulmonary/Sleep and Critical Care Service, 6900 Georgia Avenue…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Controversy remains over the optimal length of anticoagulation following idiopathic venous thromboembolism. We sought to determine if a longer, finite course of anticoagulation offered additional benefit over a short course in the initial treatment of the first episode of idiopathic venous thromboembolism. Data Extraction . Rates of deep venous thrombosis, pulmonary embolism, combined venous thromboembolism, major bleeding, and mortality were extracted from prospective trials enrolling patients with first time, idiopathic venous thromboembolism. Data was pooled using random effects meta-regression.

Results

Ten trials, with a total of 3225 patients, met inclusion criteria. For each additional month of initial anticoagulation, once therapy was stopped, recurrent venous thromboembolism (0.03 (95% CI: −0.28 to 0.35); ), mortality (−0.10 (95% CI: −0.24 to 0.04); ), and major bleeding (−0.01 (95% CI: −0.05 to 0.02); ) rates measured in percent per patient years, did not significantly change.

Conclusions

Patients with an initial idiopathic venous thromboembolism should be treated with 3 to 6 months of secondary prophylaxis with vitamin K antagonists. At that time, a decision between continuing with indefinite therapy can be made, but there is no benefit to a longer (but finite) course of therapy.

Autor:innen und Institutionen

  • Department of Pulmonary/Critical Care/Sleep Medicine, Walter Reed Army Medical Center, Pulmonary/Sleep and Critical Care Service, 6900 Georgia Avenue NW, Washington, DC 20307, USA.

Zitieren

APA

Holley, A. B., King, C. S., Jackson, J. L., & Moores, L. K. (2010). Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis. Thrombosis. https://doi.org/10.1155/2010/540386

Vancouver

Holley AB, King CS, Jackson JL, Moores LK. Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis. Thrombosis. 2010. doi:10.1155/2010/540386

BibTeX
@article{Holley2010,
  author = {Holley, Aaron B and King, Christopher S and Jackson, Jeffrey L and Moores, Lisa K},
  title = {Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis},
  journal = {Thrombosis},
  year = {2010},
  doi = {10.1155/2010/540386}
}
Kostenlos starten →